Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter, First in Human Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Oral AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)

NCT05865002 is registered in ClinicalTrials.gov with Aurigene Discovery Technologies Limited as lead sponsor.

NCT NCT05865002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05865002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter, First in Human Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Oral AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Lead sponsor
Aurigene Discovery Technologies Limited
Phase
Phase 1
Overall status
Recruiting
Start date
September 5, 2023
Completion date
June 30, 2027
Enrollment
50 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed malignant solid neoplasm